To include your compound in the COVID-19 Resource Center, submit it here.

Catalyst falls on CPP-109 Phase IIb miss

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) fell $0.95 (66%) to $0.50 on Thursday after the company reported that CPP-109 missed the primary endpoint of

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE